IL6 and type 2 diabetes mellitus: This is in accordance with previously published report highlighting those patients with type 2 diabetes treated with IL-1β-inhibitors exhibit reductions in hs-CRP and IL-6 without changes in HbA1c (Everett et al., 2018).